Collegium paid $650 million in cash for a product generating roughly 760,000 prescriptions in 2025 — a multiple that only makes sense if you believe AZSTARYS is dramatically undercommercialised under Corium’s ownership. That is precisely the bet Collegium is making, and the numbers do not leave much room for a slow start.
The deal structure reveals the strategic logic clearly. Collegium funded the acquisition with $350 million of its own cash and a $300 million draw on an existing credit facility, then immediately raised 2026 revenue guidance by $60–70 million for AZSTARYS alone while projecting over $50 million in annual run-rate synergies within twelve months. Those synergies are almost entirely cost-side: AZSTARYS drops onto a commercial infrastructure already built for JORNAY PM, meaning Collegium avoids the duplicative sales force and medical affairs spend that burdened Corium. The incremental Adjusted EBITDA contribution relative to the incremental revenue — guidance moved $40–60 million on revenues that rose only $60–70 million — implies margin on the acquired product above 60%. That is not coincidental; it is the entire acquisition thesis.
The patent runway to December 2037 across six Orange Book-listed patents matters more than any single-year revenue figure. Collegium has consistently demonstrated that it builds for duration, not for near-term pop. JORNAY PM anchors morning-to-evening ADHD coverage; serdexmethylphenidate, a prodrug of dexmethylphenidate, offers a differentiated pharmacokinetic profile. Together they give prescribers a two-product ADHD conversation, which improves representative productivity and deepens payer contract leverage simultaneously. An up-to-$135 million contingent payment tied to commercial and manufacturing milestones shows Collegium structured downside protection intelligently — Corium only gets the full premium if AZSTARYS actually scales.
The simultaneous departures of both the Chief Commercial Officer and Chief Medical Officer introduce real execution risk at the worst possible moment — a complex product integration during a commercial ramp. The single number worth monitoring over the next two quarters is AZSTARYS prescription volume growth rate, specifically whether weekly TRx accelerates from the 2025 baseline once Collegium’s salesforce fully activates. If volume stalls despite the infrastructure advantage, the $650 million entry price looks considerably less disciplined.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
